View Item 

Show simple item record

An Evaluation of the Early Pharmacodynamic Response After Simultaneous Initiation of Warfarin and Amiodarone
dc.contributor.authorEdwin, Stephanie B.en_US
dc.contributor.authorJennings, Douglas L.en_US
dc.contributor.authorKalus, James S.en_US
dc.date.accessioned2013-04-08T20:49:35Z
dc.date.available2013-04-08T20:49:35Z
dc.date.issued2010-06en_US
dc.identifier.citationEdwin, Stephanie B.; Jennings, Douglas L.; Kalus, James S. (2010). "An Evaluation of the Early Pharmacodynamic Response After Simultaneous Initiation of Warfarin and Amiodarone." The Journal of Clinical Pharmacology 50(6). <http://hdl.handle.net/2027.42/97172>en_US
dc.identifier.issn0091-2700en_US
dc.identifier.issn1552-4604en_US
dc.identifier.urihttps://hdl.handle.net/2027.42/97172
dc.publisherWiley Periodicals, Inc.en_US
dc.publisherBlackwell Publishing Ltden_US
dc.subject.otherAmiodaroneen_US
dc.subject.otherWarfarinen_US
dc.subject.otherAnticoagulationen_US
dc.subject.otherAtrial Fibrillationen_US
dc.subject.otherDrug Interactionen_US
dc.titleAn Evaluation of the Early Pharmacodynamic Response After Simultaneous Initiation of Warfarin and Amiodaroneen_US
dc.typeArticleen_US
dc.rights.robotsIndexNoFollowen_US
dc.subject.hlbsecondlevelPharmacy and Pharmacologyen_US
dc.subject.hlbsecondlevelPediatricsen_US
dc.subject.hlbtoplevelHealth Sciencesen_US
dc.description.peerreviewedPeer Revieweden_US
dc.contributor.affiliationumDepartment of Pharmacy, University of Michigan, Ann Arboren_US
dc.contributor.affiliationotherDepartment of Pharmacy, Henry Ford Hospital, Detroit, Michiganen_US
dc.description.bitstreamurlhttp://deepblue.lib.umich.edu/bitstream/2027.42/97172/1/0091270009351885.pdf
dc.identifier.doi10.1177/0091270009351885en_US
dc.identifier.sourceThe Journal of Clinical Pharmacologyen_US
dc.identifier.citedreferenceLu Y, Won KA, Nelson BJ, Qi D, Rausch DJ, Asinger RW. Characteristics of the amiodarone‐warfarin interaction during long‐term follow‐up. Am J Health Syst Pharm. 2008; 65: 947 – 952.en_US
dc.identifier.citedreferenceGo AS, Hylek EM, Phillips KA, et al. Prevalence of diagnosed atrial fibrillation in adults: national implications for rhythm management and stroke prevention: the Anticoagulation and Risk Factors in Atrial Fibrillation (ATRIA) Study. JAMA. 2001; 285: 2370 – 2375.en_US
dc.identifier.citedreferenceFuster V, Ryden LE, Asinger RW, et al. American College of Cardiology/American Heart Association Task Force on Practice Guidelines. European Society of Cardiology Committee for Practice Guidelines and Policy Conferences North American Society of Pacing and Electrophysiology. ACC/AHA/ESC Guidelines for the Management of Patients With Atrial Fibrillation: Executive Summary: A Report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines and the European Society of Cardiology Committee for Practice Guidelines and Policy Conferences. Developed in collaboration with the North American Society of Pacing and Electrophysiology. Circulation. 2001; 104: 2118 – 2150.en_US
dc.identifier.citedreferenceRoy D, Talajic M, Dorian P, et al. Amiodarone to prevent recurrence of atrial fibrillation. N Engl J Med. 2000; 342: 913 – 920.en_US
dc.identifier.citedreferenceSingh BN, Singh SN, Reda DJ, et al. Amiodarone versus sotalol for atrial fibrillation. N Engl J Med. 2005; 352: 1861 – 1872.en_US
dc.identifier.citedreferenceLafuente‐Lafuente C, Mouly S, Longas‐Tejero MA, et al. Antiarrhythmics for maintaining sinus rhythm after cardioversion of atrial fibrillation. Cochrane Database Syst Rev. 2007; ( 4 ): CD005049.en_US
dc.identifier.citedreferenceSanoski CA, Bauman JL. Clinical observations with the amiodarone/warfarin interaction: dosing relationships with long‐term therapy. Chest. 2002; 121: 19 – 23.en_US
dc.identifier.citedreferenceKerin NZ, Blevins RD, Goldman L, et al. The incidence, magnitude, and time course of the amiodarone‐warfarin interaction. Arch Intern Med. 1988; 148: 1779 – 1781.en_US
dc.identifier.citedreferenceAlmog S, Shafran N, Halkin H, et al. Mechanism of warfarin potentiation by amiodarone: dose‐ and concentration‐dependent inhibition of warfarin elimination. Eur J Clin Pharmacol. 1985; 28: 257 – 261.en_US
dc.identifier.citedreferenceWatt AH, Stephens MR, Buss DC, et al. Amiodarone reduces plasma warfarin clearance in man. Br J Clin Pharmacol. 1985; 20: 707 – 709.en_US
dc.identifier.citedreferenceHamer A, Peter T, Mandel WJ, et al. The potentiation of warfarin anticoagulation by amiodarone. Circulation. 1982; 65: 1025 – 1029.en_US
dc.identifier.citedreferenceHolbrook AM, Pereira JA, Labris R, et al. Systematic overview of warfarin and its drug and food interactions. Arch Intern Med. 2005; 165: 1095 – 1106.en_US
dc.identifier.citedreferenceCrowther MA, Harrison L, Hirsh J. Warfarin: less may be better. Ann Intern Med. 1997; 127: 333.en_US
dc.identifier.citedreferenceCrowther MA, Ginsberg JB, Kearon C, et al. A randomized trial comparing 5‐mg and 10‐mg warfarin loading doses. Arch Intern Med. 1999; 159: 46 – 48.en_US
dc.identifier.citedreferenceHarrison L, Johnston M, Massicotte MP, Crowther M, Moffat K, Hirsh J. Comparison of 5‐mg and 10‐mg loading doses in initiation of warfarin therapy. Ann Intern Med. 1997; 126: 133 – 136.en_US
dc.identifier.citedreferenceAnsell J, Hirsh J, Hylek E, Jacobson A, Crowther M, Palareti G. Pharmacology and management of vitamin K antagonists. Chest. 2008; 133: 160S – 198S.en_US
dc.identifier.citedreferenceJuurlink DN, Gomes T, Ko DT, et al. A population‐based study of the drug interaction between proton pump inhibitors and clopidogrel. CMAJ. 2009; 180: 713 – 718.en_US
dc.identifier.citedreferenceHo PM, Maddox TM, Wang L, et al. Risk of adverse outcomes associated with concomitant use of clopidogrel and proton pump inhibitors following acute coronary syndrome. JAMA. 2009; 301: 937 – 944.en_US
dc.owningcollnameInterdisciplinary and Peer-Reviewed


Files in this item

Name:
0091270009351885.pdf
Size:
175.2KB
Format:
PDF
View/Open

Show simple item record

Remediation of Harmful Language

The University of Michigan Library aims to describe library materials in a way that respects the people and communities who create, use, and are represented in our collections. Report harmful or offensive language in catalog records, finding aids, or elsewhere in our collections anonymously through our metadata feedback form. More information at Remediation of Harmful Language.

Accessibility

If you are unable to use this file in its current format, please select the Contact Us link and we can modify it to make it more accessible to you.